Our Publications
Below we provide links to posters and publications by Pharmetheus affiliates in chronological order.
Please note that access to some publications may require a subscription.
2022
Meyer C, Dierick I, Gauderat G, Langenhorst J, Sarr C, Leroux E, Chenel M, Fouliard S, Passier P.
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
Pharmetheus Affiliates
Xiong W, Papasouliotis O, Jonsson EN, Strotmann R, Girard P
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study. Cancer Chemotherapy and Pharmacology. 2022 Apr 6:1-5.
Pharmetheus Affiliates
Jonsson EN, Nyberg J.
A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses
Pharmetheus Affiliates
Yngman G, Bjugård Nyberg H, Nyberg J, Jonsson EN, Karlsson MO
An introduction to the full random effects model
Pharmetheus Affiliates
2021
Kotani N, Dolton M, Svensson RJ, Ribbing J, Friberg LE, Vadhavkar S, Cheung D, Staton T, Sperinde G, Jin J, Putnam WS.
Population pharmacokinetics and exposure-response relationships of astegolimab in patients with severe asthma
Pharmetheus Affiliates
Tomita Y, Hansson E, Mazuir F, Wellhagen G, Ooi QX, Mezzalana E, Kitamura A, Nemoto D, Bolze S.
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
Pharmetheus Affiliates
Bergstrand M, Hansson E, Delaey B, Callewaert F, De Passos Sousa R, Sargentini‐Maier ML.
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
Pharmetheus Affiliates
Tosca EM, Gauderat G, Fouliard S, Burbridge M, Chenel M, Magni P.
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach
Pharmetheus Affiliates
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R.
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
Pharmetheus Affiliates
Schmid U, Weber B, Sarr C, Freiwald M.
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Pharmetheus Affiliates
Valenzuela B, Pérez-Ruixo JJ, Leirens Q, Ouwerkerk-Mahadevan S, Poggesi I
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis
Pharmetheus Affiliates
Smania G, Jonsson EN
Conditional distribution modeling as an alternative method for covariates simulation: comparison with joint multivariate normal and bootstrap techniques
Pharmetheus Affiliates
Schmid U, Weber B, Magnusson MO, Freiwald M
Exposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease
Pharmetheus Affiliates
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR.
Pharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous Thromboembolism
Pharmetheus Affiliates
Sjögren E, Tarning J, Barnes KI, Jonsson EN
A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
Pharmetheus Affiliates
2020
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JD, Nock V, Fleury A
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
Pharmetheus Affiliates
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R.
Population RTTE analysis of exacerbations in asthma patients: a novel approach for predicting asthma exacerbations based on biomarkers, spirometry and diaries/questionnaires
Pharmetheus Affiliates
Roeshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell L, Joseph D, Tartakovsky I, Gropper S, Reilly P, Brueckmann M, Brandão L, on Behalf of the Study Investigators .
Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism
Pharmetheus Affiliates
Anziano RJ, Milligan P
Model Informed Drug Development: Collaboration Through A Common Framework
Pharmetheus Affiliates
Mitra A, Suarez-Sharp S, Pepin XJH, Flanagan T, Zhao Y, Kotzagiorgis E, Parrott N, Sharan S, Tistaert C, Heimbach T, Zolnik B, Sjögren E, Wu F, Anand O, Kakar S, Li M, Veerasingham S, Kijima S, Lima Santos GM, Ning B, Raines K, Rullo G, Mandula H, Delvadia P, Dressman J, Dickinson PA, Babiskin A.
Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report
Pharmetheus Affiliates
Pepin X, Dressman J, Parrott N, Delvadia P, Mitra A, Zhang X, Babiskin A Kolhatkar V Seo P Taylor L Sjögren E Butler J Kostewicz E Tannergren C Koziolek M Kesisoglou F Dallmann A Zhao Y Suarez-Sharp S
In Vitro Biopredictive Methods: A Workshop Summary Report
Pharmetheus Affiliates
2019
Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Ramusovic S, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjögren E, Solodenko J, Staab A, Teutonico D
Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
Pharmetheus Affiliates
Schoemaker R, Nayak S, Harnisch LO, Karlsson MO; VISTA-ICH Collaboration
Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage
Pharmetheus Affiliates
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa R.
Effect of plasma exchange on the pharmacokinetics and pharmacodynamics of Caplacizumab, PS1487
Pharmetheus Affiliates
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa R.
Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura, PB2249
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Plan EL, Nyberg J, Kankanwadi S, Karlsson MO
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
Pharmetheus Affiliates
Bergstrand M, Hansson E, Sargentini-Maier L
Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling
Pharmetheus Affiliates
Kristoffersson A, Röshammar D, Plan EL
Assessment of expected drug exposure relative maximum safety limits in early phase studies
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Plan EL, Acharya C, Yngman G, Nyberg J, Hooker AC, Kankanwadi S, Karlsson MO
Model based support to biosimilarity assessment planning – A case study of pegfilgrastim
Pharmetheus Affiliates
Nyberg J, Karlsson MO, Jonsson EN
Implicit and efficient handling of missing covariate information using full random effects modelling
Pharmetheus Affiliates
Sjögren E, Jonsson EN
A PBPK Framework to Predict Drug Exposure in Malnourished Children
Pharmetheus Affiliates
Sarr C, Magnusson MO, Vajjah P, Zamacona M
Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis
Pharmetheus Affiliates
Nyberg J, Jonsson EN, Karlsson MO, Häggström J, members of the HBGDki Community
Properties of the full random effect modelling approach with missing covariates
Pharmetheus Affiliates
Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, Sjögren E, Tsakalozou E, Seo P, Li M, Zhang X, Lin HP, Montague T, Mitra A, Morris D, Patel N, Kesisoglou F
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report
Pharmetheus Affiliates
Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN, Friberg LE
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients
Pharmetheus Affiliates
2018
Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO
Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans
Pharmetheus Affiliates
Terranova N, Smith MK, Nordgren R, Comets E, Lavielle M, Harling K, Hooker AC, Sarr C, Mentré F, Yvon F, Swat MJ
The Standard Output: A Tool-Agnostic Modeling Storage Format.
Pharmetheus Affiliates
Suarez-Sharp S, Cohen M, Kesisoglou F, Abend A, Marroum P, Delvadia P, Kotzagiorgis E, Li M, Nordmark A, Bandi N, Sjögren E, Babiskin A, Heimbach T, Kijima S, Mandula H, Raines K, Seo P, Zhang X
Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Pharmetheus Affiliates
Jonsson EN, Harling K
Increasing the efficiency of the covariate search algorithm in the SCM
Pharmetheus Affiliates
Kantasiripitak W, Sjögren E, Magnusson MO
Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole
Pharmetheus Affiliates
Rasmussen CH, Smith MK, Ito K, Sundararajan V, Magnusson MO, Jonsson NE, Fostvedt L, Burger P, McFadyen L, Tensfeldt TG, Nicholas T
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow
Pharmetheus Affiliates
2017
Friberg Hietala S, Manolis E, Musuamba F T
A Regulatory View on Dose Finding Studies and on the Value of Dose-Exposure-Response Analysis
In O’Quigley J., Iasonos A., Bornkamp B., (Eds.), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Boca Raton FL:CRC Press
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month ormulation in Patients with Schizophrenia Based on Population PharmacokineticModeling and Simulation, and Clinical Trial Data
Pharmetheus Affiliates
Dosne AG, Bergstrand M, Karlsson MO
An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty
Pharmetheus Affiliates
Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ
Open innovation: Towards sharing of data, models and workflows
Pharmetheus Affiliates
Yngman G, Nyberg J, Jonsson EN, Karlsson MO
Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling
Pharmetheus Affiliates
Röshammar D, Bergstrand M, Andersson T, Storey R.F, Hamrén B
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
Pharmetheus Affiliates
2016
Slejko JF, Willke RJ, Ribbing J, Milligan P
Translating Pharmacometrics to a Pharmacoeconomic Model of COPD
Pharmetheus Affiliates
Röshammar D, Nyberg J, Andersson T, Stanski D, Storey RF, Hamrén B
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction
Pharmetheus Affiliates
Nguyen T, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson M, Mould D, Pérez Ruixo J, Plan EL, Savic R, van Hasselt J, Weber B, Zhou C, Comets E, Mentré F for the Model Evaluation Group of the International Society of Pharmacometrics (ISoP)
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
Pharmetheus Affiliates
van Schaick E, Benninga MA, Levine A, Magnusson MO, Troy S
Development of apopulation pharmacokinetic model of prucalopride in children with functional constipation
Pharmetheus Affiliates
Magnusson MO
Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder
Pharmetheus Affiliates
Jonsson EN, Xie R, Marshall SF, Arends RH
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
Pharmetheus Affiliates
Jonsson EN, Nyberg J, Häggström J, Lifecycle Auxology & Neurocognitive Development team, representing the Healthy Birth, Growth and Development knowledge integration (HBGDki) community
Determinants for physical growth patterns in low- and middle-income countries
Pharmetheus Affiliates
Magnusson MO, Plan EL, Remy A, König M, Aigner S, Braun V, Zipp D, Zhou X, Wolter R, Schüttrumpf J, Wartenberg-Demand A, Dälken B, Rharbaoui F
Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis
Pharmetheus Affiliates
2015
Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M
A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
Pharmetheus Affiliates
Khariton T, Jonsson EN, Bergstrand M, Carrothers TJ, Ghahramani P
Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD)
Pharmetheus Affiliates
Khariton T, Jonsson EN, Bergstrand M, Carrothers TJ, Ghahramani P
PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD)
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A.
Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A
Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation
Pharmetheus Affiliates
2014
Plan EL
Modeling and simulation of count data
Pharmetheus Affiliates
Khariton T, Bergstrand M, Plan EL, Ghahramani P
A Population PKPD Model for Changes in Sexual Function Questionnaire (CSFQ) in Patients with Major Depressive Disorder (MDD) Treated with Vilazodone or Placebo
Pharmetheus Affiliates